

**IMAGINE THIS:
A WAY TO
HELP RESTORE
WHAT'S YOURS**



Understanding Vitiligo

Vitiligo develops in genetically susceptible individuals when environmental triggers induce stress responses in the skin. This causes an autoimmune response in which melanocytes (pigment-producing cells in the skin)

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210</p

The Process of Repigmentation

Repigmentation may occur once the inflammatory response is suppressed and melanocyte precursors are stimulated to proliferate, migrate, and become mature melanocytes which can slowly begin to produce pigment.³

The main sources of melanocytes and melanocyte precursors are the hair follicles and the epidermis at the lesion borders.³ The precise molecular and cellular mechanisms underlying vitiligo repigmentation remain to be confirmed.¹

Repigmentation is a gradual process that can take weeks to months depending on the location of the lesion on the body.³

Illustration adapted from Reference 8.






What is Lumirix® work?


Lumirix® contains the active substance Ruxolitinib, a Janus kinase (JAK) inhibitor.⁶

Lumirix® is free from steroids.⁶

Lumirix® is used on the skin to treat non-segmental vitiligo with facial involvement in adults and adolescents from 12 years.⁶



Starting Lumirix®



Apply a thin layer of cream twice daily to the affected areas of your skin.⁶



Wait at least 8 hours between applications.⁶

The cream should not be used on more than 10% of your body.
Do not use more than 2 tubes of Lumirix® 100g in a month.⁶

Your doctor will recommend a treatment plan for you including how long you should use the cream.

The re-pigmentation process varies for each patient but would require months of continuous treatment.

It is important that you adhere to the prescribed dosing regimen for optimal results. Typically, you should be able to see repigmentation from 3 months onwards.⁷




Maintaining your results




了解白蝕症

當環境因素誘發皮膚壓力反應時，遺傳風險較高的人士會有機會出現白蝕症。這會引起自體免疫反應，當中黑色素細胞

JAK-STAT的啟動和炎症性的循環觸發對黑色素細胞的攻擊。



導致黑色素細胞死亡和色素脫失。





插圖改編自參考文獻 8。

色素恢復的過程

一旦發炎反應被抑制，黑色素細胞前驅細胞被刺激增生、遷移並成為成熟的黑色素細胞，可慢慢開始產生色素進行修復。³

色素恢復是一個漸進的過程，可能需要數週到數月的時間，具體時間取決於身體病變的位置。³白蝕症背後精確的分子和細胞機制仍有待確認。¹







開始 Lumirix® 治療



每天在受影響的皮膚區域塗抹一層薄薄的藥膏兩次。兩次之間至少相隔8小時。⁶

藥膏的使用面積不得超過身體面積的10%。一個月內不要使用超過 2 支 Lumirix® 100g。⁶


維持您的治療目標

一旦您實現了治療目標，請與您的醫生

討論如何維持治療效果並防止復發。

您的醫生將為您推薦治療方案，包括應使用藥膏多長時間。每個患者色素恢復的進展各不相同，但一般需要數月的持續治療。

遵守規定的用藥方案以獲得最佳效果是非常重要。一般情況下，您應該在 3 個月後能夠看到色素恢復。⁷





Lumirix®

Ruxolitinib Cream 15mg/g

欲了解更多資訊，請諮詢您的醫生。
本手冊旨在由醫生派發給已處方Lumirix®的患者。



c/o 盧凱業務發展有限公司（代理）
香港北角英皇道510號港運大廈21樓2106

References:

1. Frisoli ML, et al. 'Vitiligo: Mechanisms of Pathogenesis and Treatment'. Annual Review of Immunology 2020;38:621–48.
2. Qi F, Liu F, Gao L. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Front Immunol. 2021 Nov 18;12:790125.
3. Birlea SA, Goldstein NB, Norris DA. Repigmentation through melanocyte regeneration in vitiligo. Dermatol Clin. 2017;35(2):205-218. doi:10.1016/j.det.2016.11.015.
4. Utama A, et al. 'Janus Kinase Inhibitors and the Changing Landscape of Vitiligo Management: A Scoping Review'. International Journal of Dermatology 2024;63:1020-35.
5. Hwang JR, Driscoll MS. Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo. Annals of Pharmacotherapy. 2023;57(8):948-955
6. Hong Kong Lumirix® cream Prescribing Information.
7. Rosmarin D, et al. 'Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo'. The New England Journal of Medicine 2022;387:1445-55.
8. Incyte. "Discover The role of The Jak-stat Pathway in vitiligo." Accessed Jan 22, 2025. <https://www.vitiligodeeper.com/jak-stat-pathway>.